Modafinil: Mechanisms of action

Narcolepsy and Hypersomnia

Volumn , Issue , 2006, Pages 547-560

  Scammell, Thomas E ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85056675988     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (76)

1. Espana RA, Scammell TE. Sleep neurobiology for the clinician. Sleep, 2004; 27(4):811-820.
2. Hunsley MS, Palmiter RD. Norepinephrine-deficient mice exhibit normal sleep-wake states but have shorter sleep latency after mild stress and low doses of amphetamine. Sleep, 2003; 26(5):521-526.
3. Aston-Jones G, Chen S, Zhu Y, Oshinsky ML. A neural circuit for circadian regulation of arousal. Nat Neurosci, 2001; 4(7):732-738.
4. Parmentier R., Ohtsu H, Djebbara-Hannas Z, Valatx JL, Watanabe T, Lin JS JSAnatomical, physiological, and pharmacological characteristics of histidine decarboxylase knock-out mice: evidence for the role of brain histamine in behavioral and sleep-wake control. J Neurosci, 2002; 22(17):7695-7711.
5. John J, Wu MF, Boehmer LN, Siegel JM. Cataplexy-active neurons in the hypothalamus: implications for the role of histamine in sleep and waking behavior. Neuron, 2004; 42(4):619-634.
6. Trulson ME. Simultaneous recording of substantia nigra neurons and voltammetric release of dopamine in the caudate of behaving cats. Brain Res Bull, 1985; 15(2):221-223.
7. Jones BE, Bobillier P, Pin C, Jouvet M. The effect of lesions of catecholamine-containing neurons upon monoamine content of the brain and EEG and behavioral waking in the cat. Brain Res, 1973; 58(1):157-177.
8. Lu J, Xu M, Saper C. Identification of wake-active dopaminergic neurons in the ventral periaqueductal gray (PAG). Jour Neurosci 26(1):193-202.
9. Gainetdinov RR, Caron MG. Monoamine transporters: from genes to behavior. Annu Rev Pharmacol Toxicol, 2003; 43:261-284.
10. Schmitz Y, Lee CJ, Schmauss C, Gonon F, Sulzer D. Amphetamine distorts stimulation-dependent dopamine overflow: effects on D2 autoreceptors, transporters, and synaptic vesicle stores. J Neurosci, 2001; 21(16):5916-5924.
11. Davids E, Zhangf K, Kula NS, Tarazi FI, Baldessarini RJ. Effects of norepinephrine and serotonin transporter inhibitors on hyperactivity induced by neonatal 6-hydroxydopamine lesioning in rats. J Pharmacol Exp Ther, 2002; 301(3):1097-1102.
12. Fischer JF, Cho AK. Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model. J Pharmacol Exp Ther, 1979; 208(2):203-209.
13. Saunders C, Ferre JV, Shi L, Chen J, Merril G, Lamb ME, Leeb-Lundberg LM, Carvelli L, Javitch JA, Galli A, Amphetamine-induced loss of human dopamine transporter activity: an internalizationdependent and cocaine-sensitive mechanism. Proc Natl Acad Sci U S A, 2000; 97(12):6850-6855.
14. Jones SR, Gainetdinov RR, Jaber M, Giros B, Wightman RM, Caron MG. Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J Neurosci, 1998; 18(6):1979-1986.
15. Brown JM., Hanson GR, Fleckenstein AE, Methamphetamine rapidly decreases vesicular dopamine uptake. J Neurochem, 2000; 74(5):2221-2223.
16. Takahashi N, Miner LL, Sora I, Ujike H, Revay RS, Kostic V, Jackson-Lewis V, Przedborski S, Uhl GR., VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc Natl Acad Sci U S A, 1997; 94(18):9938-9943.
17. Fon EA, Pothos EN, Sun BC, Killeen N, Sulzer D, Edwards RH. Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action. Neuron, 1997; 19(6):1271-1283.
18. Gonzalez AM, Walther D, Pazos A, Uhl GR. Synaptic vesicular monoamine transporter expression: distribution and pharmacologic profile. Brain Res Mol Brain Res, 1994; 22(1-4):219-226.
19. Sulzer D, Rayport S. Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action. Neuron, 1990; 5(6):797-808.
20. Mantle TJ., Tipton KF, Garrett NJ. Inhibition of monoamine oxidase by amphetamine and related compounds. Biochem Pharmacol, 1976; 25(18):2073-2077.
21. Nishino S, Mao J, Sampathkumaran R, Shelton J, Mignot E Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Res Online, 1998; 1(1):49-61.
22. Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM Dopaminergic role in stimulant-induced wakefulness. J Neurosci, 2001; 21(5):1787-1794.
23. Jones BE., Harper ST, Halaris AE, Effects of locus coeruleus lesions upon cerebral monoamine content, sleep-wakefulness states and the response to amphetamine in the cat. Brain Res, 1977; 124(3):473-496.
24. Xu F, Gainetdinov RR, Wetsel WC, Jones SR, Bohn LM, Miller GW, Wang YM, Caron MG, Mice lacking the norepinephrine transporter are supersensitive to psychostimulants. Nat Neurosci, 2000; 3(5):465-471.
25. Duteil J, Rambert FA, Pessonnier J, Hermant JF, Gombert R, Assous E., Central alpha 1-adrenergic stimulation in relation to the behaviour stimulating effect of modafinil; studies with experimental animals. Eur J Pharmacol, 1990; 180(1):49-58.
26. Lin JS, Roussel B, Akaoka H, Fort P, Debilly G, Jouvet M. Role of catecholamines in the modafinil and amphetamine induced wakefulness, a comparative pharmacological study in the cat. Brain Res, 1992; 591(2):319-326.
27. Mignot E, Nishino S, Guillemeinault C, Dement WC. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep, 1994; 17(5):436-437.
28. Drouin C, Darracq L, Trovero F, Blanc G, Glowinski J, Cotecchia S, Tassin JP Alpha1b-adrenergic receptors control locomotor and rewarding effects of psychostimulants and opiates. J Neurosci, 2002; 22(7):2873-2884.
29. Shelton J, Nishino S, Vaught J, Dement WC, Mignot E., Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs. Sleep, 1995; 18(10):817-826.
30. Edgar DM, Seidel WF, Modafinil induces wakefulness without intensifying motor activity or subsequent rebound hypersomnolence in the rat. J Pharmacol Exp Ther, 1997; 283(2):757-769.
31. Saletu, B, Saletu M, Grunberger J, Frey R, Anderer P, Mader R. Treatment of the alcoholic organic brain syndrome: double-blind, placebo-controlled clinical, psychometric and electroencephalographic mapping studies with modafinil. Neuropsychobiology, 1993; 27(1):26-39.
32. Jasinski DR. An evaluation of the abuse potential of modafinil using methylphenidate as a reference. in Congress on Problems in Drug Dependance. 1997. Nashville.
33. Buguet A, Montmayeur A, Pigeau R, Naitoh P. Modafinil, d-amphetamine and placebo during 64 hours of sustained mental work. II. Effects of two nights of recovery sleep. J. Sleep Res., 1995; 4:229-241.
34. Wong, YN Wang L, Hartman L, Simcoe D, Chen Y, Laughton W, Eldon R, Markland C, Grebow P. Comparison of the single-dose pharmacokinetics and tolerability of modafinil and dextroamphetamine administered alone or in combination in healthy male volunteers. J Clin Pharmacol, 1998; 38(10):971-978.
35. Hermant JF, Rambert FA, Duteil J. Awakening properties of modafinil: effect on nocturnal activity in monkeys (Macaca mulatta) after acute and repeated administration. Psychopharmacology (Berl), 1991; 103(1):28-32.
36. Rush, CR, Kelly TH, Hays LR, Baker RW, Wooten AF. Acute behavioral and physiological effects of modafinil in drug abusers. Behav Pharmacol, 2002; 13(2):105-115.
37. Makris AP, Rush CR, Frederich RC, Kelly TH. Wake-promoting agents with different mechanisms of action: comparison of effects of modafinil and amphetamine on food intake and cardiovascular activity. Appetite, 2004; 42(2):185-195.
38. Wong YN, Wang L, Hartman, Simcoe D, Chen Y, Laughton W, Eldon R, Markland C, Grebow P.., A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J Clin Pharmacol, 1999; 39(1):30-40.
39. Billiard M, Besset A, Montplaisir J, Laffont F, Goldenberg F, Weill JS, Lubin S. Modafinil: a doubleblind multicentric study. Sleep, 1994; 17(8 Suppl):S107-S112.
40. Broughton RJ, Fleming JAE, George CFP, Hill JD, Kryger MH, Moldofsky H, Montplaisir J, Morehouse RL, Moskovitch A, Murphy WF. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology, 1997; 49(2):444-451.
41. Saletu B, Saletu M, Grunberger J, Frey R, Zatschek I Mader., On the treatment of the alcoholic organic brain syndrome with an alpha-adrenergic agonist modafinil: double-blind, placebo-controlled clinical, psychometric and neurophysiological studies. Prog Neuropsychopharmacol Biol Psychiatry, 1990; 14(2):195-214.
42. Moldofsky H., Broughton RJ, Hill JD. A randomized trial of the long-term, continued efficacy and safety of modafinil in narcolepsy. 2000; 1(2):109-116.
43. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology, 2000; 54(5):1166-1175.
44. Sackner-Bernstein J,. Niebler G and C. Earl C. Effect of the Centrally Acting Wake-Promoting Agent Modafinil on Blood Presure and heart Rate. SLEEP, 2003; 26:A80.
45. Tanganelli S, Fuxe K, Ferraro L, Janson AM, Bianchi C. Inhibitory effects of the psychoactive drug modafinil on gamma-aminobutyric acid outflow from the cerebral cortex of the awake freely moving guinea-pig. Possible involvement of 5-hydroxytryptamine mechanisms. Naunyn Schmiedebergs Arch Pharmacol, 1992; 345(4):461-465.
46. Tanganelli S, Perez de la Mora, Ferraro L, Mendez-Franco J, Beani L, Rambert FA, Fuxe K. Modafinil and cortical gamma-aminobutyric acid outflow. Modulation by 5-hydroxytryptamine neurotoxins. Eur J Pharmacol, 1995; 273(1-2):63-71.
47. Ferraro L, Tanganelli S, OConnor WT, Antonelli T, Rambert FA, Fuxe K. The vigilance promoting drug modafinil increases dopamine release in the rat nucleus accumbens via the involvement of a local GABAergic mechanism. Eur J Pharmacol, 1996; 306(1-3):33-39.
48. Ferraro L, Antonelli T, Tanganelli S, OConnor WT, Perez de la Mora M, Mendez-Franco J, Rambert FA. The vigilance promoting drug modafinil increases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: prevention by local GABAA receptor blockade. Neuropsychopharmacology, 1999; 20(4):346-356.
49. Perez de la Mora, M., Aguilar-Garcia A, Ramon-Frias T, Ramirez-Ramirez R, Mendez-Franco J, Rambert F, Fuxe K., Effects of the vigilance promoting drug modafinil on the synthesis of GABA and glutamate in slices of rat hypothalamus. Neurosci Lett, 1999; 259(3):181-185.
50. Tanganelli S, Ferraro L, Bianchi C, Fuxe K. 6-hydroxy-dopamine treatment counteracts the reduction of cortical GABA release produced by the vigilance promoting drug modafinil in the awake freely moving guinea-pig. Neurosci Lett, 1994; 171(1-2):201-204.
51. Ferraro L, Tanganelli S, OConnor WT, Antonelli T, Rambert F, Fuxe K. The vigilance promoting drug modafinil decreases GABA release in the medial preoptic area and in the posterior hypothalamus of the awake rat: possible involvement of the serotonergic 5-HT3 receptor. Neurosci Lett, 1996; 220(1):5-8.
52. Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammel TE, Lee C, Richardson JA, Williams SC, Xiong Y, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell, 1999; 98(4):437-451.
53. Scammell TE, Estabrooke IV, McCarthy MT, Chemelli RM, Yanagisawa M, Miller MS, Saper CB Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci, 2000; 20(22):8620-8628.
54. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol, 1998; 43(1):88-97.
55. Willie J, Renthal W, Chemelli RM, Miller MS, Scammel TE, Yanagisawa M, Sinton CML. Modafinil more effectively induces wakefulness in orexin-null mice than in wild-type littermates. Neuroscience, 2005; 130: 983-995.
56. Lin JS, Hou Y, Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci U S A, 1996; 93(24):14128-14133.
57. Engber TM, Koury EJ, Dennis SA, Miller MS, Contreras PC, Bhat RV. Differential patterns of regional c-Fos induction in the rat brain by amphetamine and the novel wakefulness-promoting agent modafinil. Neurosci Lett, 1998; 241(2-3):95-98.
58. Ko EM, Estabrooke IV, McCarthy M, Scammell TE. Wake-related activity of tuberomammillary neurons in rats. Brain Res, 2003; 992(2):220-226.
59. Estabrooke IV, McCarthy MT, Ko E, Chou TC, Chemelli RM, Yanagisawa M, Saper CB, Scammel TE. Fos expression in orexin neurons varies with behavioral state. J Neurosci, 2001; 21(5):1656-1662.
60. LaHoste GJ, Yu J, Marshall JF. Striatal Fos expression is indicative of dopamine D1/D2 synergism and receptor supersensitivity. Proc Natl Acad Sci U S A, 1993; 90(16):7451-7455.
61. Cole AJ, Bhat RV, Patt C, Worley PF, Baraban JM. D1 dopamine receptor activation of multiple transcription factor genes in rat striatum. J Neurochem, 1992; 58(4):1420-1426.
62. de Saint Hilaire, Z., Orosco M, Rouch C, Blanc G, Nicolaidis S., Variations in extracellular monoamines in the prefrontal cortex and medial hypothalamus after modafinil administration: a microdialysis study in rats. Neuroreport, 2001; 12(16):3533-3537.
63. Fuxe K, Janson AM, Rosen, Finnman UB, Tanganelli S, Moran M, Goldstein M, Agnati LF. Evidence for a protective action of the vigilance promoting drug modafinil on the MPTP-induced degeneration of the nigrostriatal dopamine neurons in the black mouse: an immunocytochemical and biochemical analysis. Exp Brain Res, 1992; 88(1):117-130.
64. Moachon G, Kanmacher I, Clenet M, Matinier D. Pharmacokinetic profile of modafinil. Drugs of Today, 1996; 32(4):327-337.
65. Gallopin T, Luppi PH, Rambert FA, Frydman A, Fort P. Effect of the Wake-Promoting Agent Modafinil on Sleep-Promoting Neurons from the Ventrolateral Preoptic Nucleus: an In Vitro Pharmacologic Study. Sleep, 2004; 27(1):19-25.
66. Jones SR, Gainetdinov RR, Hu XT, Cooper DC, Wightman RM, White FJ, Caron MG. Loss of autoreceptor functions in mice lacking the dopamine transporter. Nat Neurosci, 1999; 2(7):649-655.
67. Gallopin T, Fort P, Eggermann E, Cauli B, Luppi PH, Rossier J, Audinat E, Muhlethaler M, Serafin M. Identification of sleep-promoting neurons in vitro. Nature, 2000; 404(6781):992-995.
68. Akaoka H, Roussel B, Lin JS, Chouvet G, Jouvet M. Effect of modafinil and amphetamine on the rat catecholaminergic neuron activity. Neurosci Lett, 1991; 123(1):20-22.
69. Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol, 1997; 52(1):27-78.
70. Ferraro L, Fuxe K, Tanganelli S, Fernandez M, Rambert FA, Antonelli T. Amplification of cortical serotonin release: a further neurochemicaal action of the vigilance-promoting drug modafinil. Neuropharmacology, 2000; 39(11):1974-1983.
71. Ferraro L, Fuxe K, Tanganelli S, Tomasini MC, Rambert FA, Antonelli T. Differential enhancement of dialysate serotonin levels in distinct brain regions of the awake rat by modafinil: possible relevance for wakefulness and depression. J Neurosci Res, 2002; 68(1):107-112.
72. Ishizuka T, Sakamoto Y, Sakurai T, Yamatodani A. Modafinil increases histamine release in the anterior hypothalamus of rats. Neurosci Lett, 2003; 339(2):143-146.
73. Simon P, Hemet C, Ramassamy C, Costentin J. Non-amphetaminic mechanism of stimulant locomotor effect of modafinil in mice. Eur Neuropsychopharmacol, 1995; 5(4):509-514.
74. Saletu, B, Freyr, Krupka M, Anderer P, Grunberger J, Barbaroj MJ, Differential effects of a new central adrenergic agonist-modafinil-and D-amphetamine on sleep and early morning behaviour in young healthy volunteers. Int J Clin Pharmacol Res, 1989; 9(3):183-195.
75. Saletu B, Frey R, Krupka M, Anderer P, Grunberger J, Barbanoj MJ. Differential effects of the new central adrenergic agonist modafinil and d-amphetamine on sleep and early morning behaviour in elderlies. Arzneimittelforschung, 1989; 39(10):1268-1273.
76. Batejat DM, Lagarde DP. Naps and modafinil as countermeasures for the effects of sleep deprivation on cognitive performance. Aviat Space Environ Med, 1999; 70(5):493-498.